Glaukos Corporation Common Stock (GKOS)

Glaukos’ two newer launches are carrying the company, and its 2027 target may be too low. Here’s what to watch.

Record sales and margin expansion driven by iDose TR and Epioxa launches.

Glaukos (NYSE:GKOS) reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma treatment. The company raised its full-year 2026 revenue outlook and introduced a preliminary target

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include:

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunction with cataract surgery compared to cataract surgery alone in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The agreement also grants Glaukos exclusive rights to RevOpsis’ proprietary RevMod™ platform in geographic atrophy, DME, DR, RVO, and nAMD for the discovery and development of up to four additional next-generation retinal biologic candidates.

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sight-threatening corneal disease that remains significantly undiagnosed and undertreated. The extension study followed a cohort of patients for three years after cross-linking treatment in Epioxa’s second Phase 3 pivotal trial (GLK-202-02).

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release third quarter 2026 financial results after the market close on Wednesday, October 28, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 28, 2026.

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational campaign launching today with expanding activities planned in 2027 aimed at improving recognition and earlier detection of keratoconus (KC), a rare, progressive, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.

Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 3.9% on an annualized basis producing an average annual return of 17.45%. Currently, Glaukos has a market capitalization of $10.58 billion.

Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized basis producing an average annual return of 26.17%. Currently, Glaukos has a market capitalization of $10.97 billion.

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA.

iDose TR drove $74M in Q2 revenue as Glaukos raised full-year guidance.

Glaukos (NYSE:GKOS) reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management’s exp

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include:

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO™ MicroShunt in adult patients with primary open-angle glaucoma (POAG) who failed previous medical and surgical treatment.

Disposition represented 19% of insider's equity holdings under pre-established Rule 10b5-1 trading plan. Thurman retains 43,681 shares worth approximately $6.77 million.

Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.